Understanding Multiple System Atrophy -Could Genetics Lead the Way? 11, 12 These findings were supported by the discovery of α-synuclein mRNA overexpression in the brains of patients with MSA. 13 This supports a hypothesis that the toxicity of α-synuclein plays an important role in the pathogenesis of this disease, and may help to pave the way for therapeutic options.
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Glucocerebrosidase gene
Glucocerebrosidase (GCase), encoded by the Glucocerebrosidase gene (GBA), is an enzyme involved in the lysosomal degradation of sphingolipids.
14 Homozygous mutations of this gene result in Gaucher's disease (GD), a rare lysosomal storage disease that is particularly prevalent in certain populations, such as the Ashkenazi Jewish population.
Parkinson's disease and DLB patients are roughly 5-10-fold 15 and 8 fold 16 (respectively) more likely to carry GBA mutations than the general population. These genetic findings have been followed up with findings of reduced GCase activity in the brains 17 and peripheral blood18 of patients with Parkinson's disease. The prevalence of GBA mutations among patients with MSA has been studied by a few groups in recent years, and has yielded varied results. [19] [20] [21] [22] [23] [24] [25] Six studies have found no association between GBA mutations and MSA.
The most recent and largest study included 969 clinically diagnosed MSA patients and 1,509 controls from Japan, several sites in Europe, and several sites in North America. 21 They found a significantly increased odds ratio for GBA variants in MSA patients compared to controls. In fact, two patients with MSA had homozygous mutations in the GBA gene without a known clinical diagnosis of GD, while none of the controls had homozygous or compound heterozygous mutations. This study certainly indicates that further study of the relationship between GBA and MSA is required. It implies that genetic testing for GD may be indicated in certain populations with MSA, and introduces another area for research into therapeutic options for MSA.
Coenzyme Q2 gene
Recently, four multiplex MSA families were studied with whole exome and subsequent linkage analysis in the attempt at identifying a candidate genetic locus for MSA. 26 In two of four Japanese families, the researchers detected mutations in the coenzyme Q2 (CoQ2) gene, which plays a role in the synthetic pathway for CoQ10. They followed this with genetic analysis of 726 Japanese patients with sporadic MSA and 1040 Japanese controls, which revealed 35 CoQ2 mutations among MSA patients and 17 among controls (OR=3.05, p=0.00015 ). An association between sporadic MSA and CoQ2 variants was found in Japanese, Taiwanese and Chinese populations, but these results were not replicated in other cohorts. [26] [27] [28] [29] [30] [31] Further studies have revealed reduction in CoQ10 levels in the cerebellum and serum of patients with MSA. 32, 33 These findings may be particularly important in implicating CoQ10 supplementation as a therapeutic option in MSA, though this has not yet been systematically studied.
Other implicated genes
A hexanucleotide expansion in the C9orf72 gene located on chromosome 9 has been found to be present in patients with familial forms of frontotemporal dementia and amyotrophic lateral sclerosis (ALS). There is also a report of clinically diagnosed MSA with C9orf72 expansion in a family with ALS. 34 Though C9orf72 expansions are associated with parkinsonian symptoms and syndromes, this is the only report of suspected MSA with C9orf72. Subsequent studies, including a series of 100 pathologically confirmed MSA cases, 35 have failed to produce a link between this expansion and MSA.
Microtubule-associated protein tau (MAPT) gene has been associated with frontotemporal dementia and ALS phenotypes as well as parkinsonism.
There does not appear to be an association between mutations in this gene and MSA, however this has not been extensively studied. 36 Mutations in the Leucine-rich repeat kinase 2 (LRRK2) have been investigated for a causal link with MSA. Most studies have not found an association between LRRK2 mutations and MSA. 37, 38 However one large series from the US and UK found a protective effect of LRRK2 variants on MSA. 39 Genetic mutations in the spinocerebellar ataxia family (SCA) are associated with varying degrees of ataxia, parkinsonism, dystonia, and even autonomic dysfunction. Given the clinical overlap with symptoms seen in MSA, it can be difficult to distinguish SCA from MSA. Patients with SCA syndromes typically present earlier in life than MSA, are usually slower in progression, and will have a family history. In clinical practice, it is often advisable to test for SCA mutations when evaluating patients presenting with adult-onset cerebellar ataxia, with or without a known family history. 40 Most studies looking at the association between clinically diagnosed MSA and mutations in the SCA genes have focused 
Conclusion
MSA is not generally considered a genetic disease, and in fact only rarely has been described in families. More recent efforts in the field of MSA genetics have revealed several candidate genes that may be involved in the pathogenesis of the disease. The pathogenesis of MSA remains an enigma, though it is becoming clear that genetic associations exist. Many mechanisms for the development and propagation of MSA have been postulated, including impaired elimination of α-synuclein within the cell, [41] [42] [43] [44] mitochondrial dysfunction, 32, 33, 45, 46 direct toxicity of α-synuclein, 47 oxidative stress, 48 and neuroinflammation. 49, 50 More recently, there are also data that implicate a prion-like propagation of MSA. 51 We are hopeful that genetic associations may give us further clues into the pathogenesis of MSA, as well as targets for therapeutic interventions. For example, if GBA mutations confer a higher risk of developing MSA, it follows that treatment with enzyme replacement therapy may offer some benefit to patients who have MSA, with or without GBA mutations. It is clear that none of the genetic associations discussed above confer a high penetrance for development of MSA; rather they likely create a pre-disposition for this rare and devastating disease. With advances in the knowledge of genetic contributions to MSA we may find clues to the understanding and treatment of this disease. q
